![]() |
AKRO | Akero Therapeutics, Inc. |
Pharmaceutical Preparations |
Book value per $ invested | $ 0.43 |
Leverage | 7.51% |
Market Cap | $ 2.4B |
PE | 0.00 |
Dividend Yield | 0.00% |
Profit | $ -283.2m |
Margin | 0.00% |
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, is dedicated to developing medications designed to restore metabolic balance and improve overall health. The company is headquartered in South San Francisco, California.